A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Solid Tumor
Unknown Primary
18 Years and older, Male and Female
LOXO-FG3-22001 (primary)
NCI-2023-00367
022-502755-59-00
2022-502755-59-00
J4G-OX-JZVA
Summary
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line
the urinary system and other solid tumor cancers that have a change in a particular gene
(known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and
possibly longer if the disease does not get worse.
Objectives
This is an open-label, multi-center, phase 1a/b study in participants with FGFR3-altered
advanced solid tumors, including metastatic urothelial cancer (UC). The study will be
conducted in 2 phases: Dose escalation and dose optimization (1a) and dose expansion
(1b). Phase 1a will include up to 2 cohorts to assess safety, tolerability, and
pharmacokinetics of LOXO-435 to determine the recommended phase 2 dose (RP2D) (or optimal
dose). Phase 1b will include 4 dose expansion cohorts of participants with prespecified
activating FGFR3 alterations to evaluate the efficacy and safety of LOXO-435 at the RP2D.
Cohort B will enroll pts with metastatic UC and includes three cohorts to evaluate
LOXO-435 as monotherapy (B1, B2) and in combination with pembrolizumab (B3). Cohort C
will enroll pts with non-UC advanced solid tumors and includes a cohort to evaluate
LOXO-435 as monotherapy (C1).
Eligibility
- Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable.
- Cohort A1 (Dose Escalation): Presence of an alteration in FGFR3 or its ligands.
- Cohort A2 (Dose Optimization): Histological diagnosis of urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 alteration.
- Cohorts B1, B2 and B3 (Dose Expansion): Histological diagnosis of urothelial cancer that is locally advanced or metastatic with a prespecified activating FGFR3 alteration.
- Cohort C (Dose Expansion): Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a prespecified activating FGFR3 alteration.
- Measurability of disease:
- Cohort A1: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1)
- Cohorts A2, B1, B2, B3, and C1: Measurable disease required as defined by RECIST v1.1
- Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country-specific regulations.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Prior Systemic Therapy Criteria:
- Cohort A1/C1: Participant has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating Investigator; OR the participant is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies.
- Cohort A2/B1/B2/B3: Participants must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.
- FGFR inhibitor specific requirements:
- Cohort A1/A2: Prior FGFR inhibitor treatment is permitted, but not required.
- Cohort B1: Participants must have been previously treated with a FGFR inhibitor.
- Cohort B2, B3, C1: Participants must be FGFR inhibitor naïve.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.